Stocks and Investing
Stocks and Investing
Tue, June 19, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, June 18, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, June 15, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Yun Zhong Initiated (SRPT) at Strong Buy and Held Target at $120 on, Jun 15th, 2018
Yun Zhong of BTIG, Initiated "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy and Held Target at $120 on, Jun 15th, 2018.
Yun has made no other calls on SRPT in the last 4 months.
There are 7 other peers that have a rating on SRPT. Out of the 7 peers that are also analyzing SRPT, 2 agree with Yun's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Hartaj Singh of "Oppenheimer" Downgraded from Buy to Hold on, Friday, May 4th, 2018
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $91 on, Friday, May 4th, 2018
These are the ratings of the 5 analyists that currently disagree with Yun
- Gena Wang of "Barclays" Upgraded from Hold to Buy on, Friday, May 11th, 2018
- Alethia Young of "Credit Suisse" Maintained at Buy with Decreased Target to $92 on, Friday, May 4th, 2018
- Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $95 on, Wednesday, March 14th, 2018
- Joseph Schwartz of "Leerink Swann" Maintained at Buy with Increased Target to $92 on, Tuesday, March 13th, 2018
- Debjit Chattopadhyay of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $92 on, Monday, March 12th, 2018